BG64622B1 - 2-(3,5-бис-трифлуорометил-фенил)-n-метил-n-(6-морфолин-4-ил)-4-о-толил-пиридин-3-ил)-изобутирамид, метод за получаване и използването му - Google Patents

2-(3,5-бис-трифлуорометил-фенил)-n-метил-n-(6-морфолин-4-ил)-4-о-толил-пиридин-3-ил)-изобутирамид, метод за получаване и използването му Download PDF

Info

Publication number
BG64622B1
BG64622B1 BG104992A BG10499200A BG64622B1 BG 64622 B1 BG64622 B1 BG 64622B1 BG 104992 A BG104992 A BG 104992A BG 10499200 A BG10499200 A BG 10499200A BG 64622 B1 BG64622 B1 BG 64622B1
Authority
BG
Bulgaria
Prior art keywords
compound
formula
tolyl
receptor
methyl
Prior art date
Application number
BG104992A
Other languages
Bulgarian (bg)
English (en)
Other versions
BG104992A (en
Inventor
Theresa Ballard
Guy Higgins
Torsten Hoffmann
Sonia Poli
Andrew Sleight
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of BG104992A publication Critical patent/BG104992A/xx
Publication of BG64622B1 publication Critical patent/BG64622B1/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
BG104992A 1999-11-29 2000-11-28 2-(3,5-бис-трифлуорометил-фенил)-n-метил-n-(6-морфолин-4-ил)-4-о-толил-пиридин-3-ил)-изобутирамид, метод за получаване и използването му BG64622B1 (bg)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99123685 1999-11-29

Publications (2)

Publication Number Publication Date
BG104992A BG104992A (en) 2001-11-30
BG64622B1 true BG64622B1 (bg) 2005-09-30

Family

ID=8239481

Family Applications (1)

Application Number Title Priority Date Filing Date
BG104992A BG64622B1 (bg) 1999-11-29 2000-11-28 2-(3,5-бис-трифлуорометил-фенил)-n-метил-n-(6-морфолин-4-ил)-4-о-толил-пиридин-3-ил)-изобутирамид, метод за получаване и използването му

Country Status (50)

Country Link
EP (1) EP1103545B1 (pl)
JP (1) JP3480835B2 (pl)
KR (1) KR100390117B1 (pl)
CN (1) CN1152016C (pl)
AR (1) AR033659A1 (pl)
AT (1) ATE253561T1 (pl)
AU (1) AU775292B2 (pl)
BG (1) BG64622B1 (pl)
BR (1) BRPI0005616B8 (pl)
CA (1) CA2326529C (pl)
CO (1) CO5251405A1 (pl)
CZ (1) CZ299286B6 (pl)
DE (2) DE60006340T2 (pl)
DK (1) DK1103545T3 (pl)
DO (1) DOP2000000106A (pl)
EA (1) EA004404B1 (pl)
ES (2) ES2208205T3 (pl)
FR (1) FR2801590A1 (pl)
GB (1) GB2356863A (pl)
GC (1) GC0000151A (pl)
GE (1) GEP20022763B (pl)
GT (1) GT200000197A (pl)
HK (1) HK1036759A1 (pl)
HR (1) HRP20000809A2 (pl)
HU (1) HU224703B1 (pl)
ID (1) ID28483A (pl)
IL (1) IL139868A (pl)
IS (1) IS2212B (pl)
IT (1) IT1320120B1 (pl)
JO (1) JO2298B1 (pl)
MA (1) MA26754A1 (pl)
MX (1) MXPA00011672A (pl)
MY (1) MY127426A (pl)
NO (1) NO317264B1 (pl)
NZ (1) NZ508386A (pl)
OA (1) OA11513A (pl)
PA (1) PA8507201A1 (pl)
PE (1) PE20010901A1 (pl)
PL (1) PL195957B1 (pl)
PT (1) PT1103545E (pl)
SG (1) SG97171A1 (pl)
SI (1) SI1103545T1 (pl)
SK (1) SK285373B6 (pl)
SV (1) SV2002000227A (pl)
TN (1) TNSN00226A1 (pl)
TR (1) TR200302077T4 (pl)
UA (1) UA70326C2 (pl)
UY (1) UY26458A1 (pl)
YU (1) YU73400A (pl)
ZA (1) ZA200006964B (pl)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE277905T1 (de) * 1999-02-24 2004-10-15 Hoffmann La Roche 4-phenylpyridinderivate und deren verwendung als nk-1 rezeptorantagonisten
CZ20013046A3 (cs) * 1999-02-24 2002-02-13 F. Hoffmann-La Roche Ag Fenylové a pyridinylové deriváty
CZ303639B6 (cs) * 2000-07-14 2013-01-23 F. Hoffmann-La Roche Ag N-Oxid derivátu 4-fenylpyridinu, zpusob jeho prípravy a lécivo s jeho obsahem
TWI287003B (en) * 2000-07-24 2007-09-21 Hoffmann La Roche 4-phenyl-pyridine derivatives
TWI259180B (en) * 2000-08-08 2006-08-01 Hoffmann La Roche 4-Phenyl-pyridine derivatives
US20030083345A1 (en) * 2001-07-10 2003-05-01 Torsten Hoffmann Method of treatment and/or prevention of brain, spinal or nerve injury
EP1472377A2 (en) * 2002-01-31 2004-11-03 F. Hoffmann-La Roche Ag Genetic polymorphisms in the preprotachykinin gene
CA2530886C (en) 2003-07-03 2013-05-28 F. Hoffmann-La Roche Ag Dual nk1/nk3 antagonists for treating schizophrenia
US7288658B2 (en) 2003-07-15 2007-10-30 Hoffmann-La Roche Inc. Process for preparation of pyridine derivatives
CA2572645C (en) 2004-07-06 2011-01-18 F. Hoffmann-La Roche Ag Process for preparing carboxamide derivatives used as intermediates in the synthesis of nk-1 receptor antagonists
CA2598762A1 (en) 2005-02-25 2006-08-31 F. Hoffmann-La Roche Ag Tablets with improved drug substance dispersibility
ES2320590T3 (es) * 2005-03-23 2009-05-25 F. Hoffmann-La Roche Ag Metabolitos para antagonistas nk-1 para emesis.
ES2335922T3 (es) * 2005-09-23 2010-04-06 F.Hoffmann-La Roche Ag Nueva formulacion de dosificacion.
CN101641099A (zh) 2007-01-24 2010-02-03 葛兰素集团有限公司 包含3,5-二氨基-6-(2,3-二氯苯基)-1,2,4-三嗪或r(-)-2,4-二氨基-5-(2,3-二氯苯基)-6-氟甲基嘧啶和nk1的药物组合物
US8426450B1 (en) 2011-11-29 2013-04-23 Helsinn Healthcare Sa Substituted 4-phenyl pyridines having anti-emetic effect
CN111454200A (zh) 2013-03-15 2020-07-28 全球血液疗法股份有限公司 化合物及其用于调节血红蛋白的用途
EP3067349B1 (en) 2013-11-08 2018-02-28 Kissei Pharmaceutical Co., Ltd. Carboxymethyl piperidine derivative
SI3102208T1 (sl) 2014-02-07 2021-07-30 Global Blood Therapeutics, Inc. Kristalinični polimorf proste baze 2-hidroksi-6-((2-(1-izopropil-1H-pirazol-5-IL)piridin-3-IL)metoksi)- benzaldehida
TWI649307B (zh) 2014-05-07 2019-02-01 日商橘生藥品工業股份有限公司 Cyclohexylpyridine derivative
KR101948238B1 (ko) 2016-08-19 2019-02-14 (주)케어젠 미녹시딜과 펩타이드의 결합체

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995016679A1 (en) * 1993-12-17 1995-06-22 Merck & Co., Inc. Morpholine and thiomorpholine tachykinin receptor antagonists
WO1995018124A1 (en) * 1993-12-29 1995-07-06 Merck Sharp & Dohme Limited Substituted morpholine derivatives and their use as therapeutic agents
WO1995023798A1 (en) * 1994-03-04 1995-09-08 Merck & Co., Inc. Prodrugs of morpholine tachykinin receptor antagonists
US5972938A (en) * 1997-12-01 1999-10-26 Merck & Co., Inc. Method for treating or preventing psychoimmunological disorders

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69231395T3 (de) * 1991-09-20 2005-07-21 Glaxo Group Ltd., Greenford Neue medizinische Indikation für Tachykinin-Antagonisten
IL106142A (en) * 1992-06-29 1997-03-18 Merck & Co Inc Morpholine and thiomorpholine tachykinin receptor antagonists, their preparation and pharmaceutical compositions containing them
TW394773B (en) * 1995-03-24 2000-06-21 Takeda Chemical Industries Ltd Cyclic compounds for antagonizing tachykinin receptor, substance p receptor and neurokinin a receptor, their production and pharmaceutical composition
ATE277905T1 (de) * 1999-02-24 2004-10-15 Hoffmann La Roche 4-phenylpyridinderivate und deren verwendung als nk-1 rezeptorantagonisten
US6303790B1 (en) * 1999-11-29 2001-10-16 Hoffman-La Roche Inc. Process for the preparation of pyridine derivatives
CZ303639B6 (cs) * 2000-07-14 2013-01-23 F. Hoffmann-La Roche Ag N-Oxid derivátu 4-fenylpyridinu, zpusob jeho prípravy a lécivo s jeho obsahem
TWI287003B (en) * 2000-07-24 2007-09-21 Hoffmann La Roche 4-phenyl-pyridine derivatives
TWI259180B (en) * 2000-08-08 2006-08-01 Hoffmann La Roche 4-Phenyl-pyridine derivatives

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995016679A1 (en) * 1993-12-17 1995-06-22 Merck & Co., Inc. Morpholine and thiomorpholine tachykinin receptor antagonists
WO1995018124A1 (en) * 1993-12-29 1995-07-06 Merck Sharp & Dohme Limited Substituted morpholine derivatives and their use as therapeutic agents
WO1995023798A1 (en) * 1994-03-04 1995-09-08 Merck & Co., Inc. Prodrugs of morpholine tachykinin receptor antagonists
US5972938A (en) * 1997-12-01 1999-10-26 Merck & Co., Inc. Method for treating or preventing psychoimmunological disorders

Also Published As

Publication number Publication date
IS5725A (is) 2001-05-29
BRPI0005616B8 (pt) 2021-07-06
CO5251405A1 (es) 2003-02-28
CN1297888A (zh) 2001-06-06
IL139868A0 (en) 2002-02-10
CZ299286B6 (cs) 2008-06-04
HK1036759A1 (en) 2002-01-18
HRP20000809A2 (en) 2001-12-31
IS2212B (is) 2007-02-15
PT1103545E (pt) 2004-03-31
ID28483A (id) 2001-05-31
ES2171134A1 (es) 2002-08-16
PL344147A1 (en) 2001-06-04
GC0000151A (en) 2005-06-29
AR033659A1 (es) 2004-01-07
GT200000197A (es) 2002-05-22
IL139868A (en) 2009-09-01
NO20006012L (no) 2001-05-30
MXPA00011672A (es) 2002-08-20
AU775292B2 (en) 2004-07-29
EP1103545A1 (en) 2001-05-30
EA004404B1 (ru) 2004-04-29
JP3480835B2 (ja) 2003-12-22
SK17932000A3 (sk) 2001-11-06
UA70326C2 (en) 2004-10-15
HU0004725D0 (pl) 2001-02-28
BG104992A (en) 2001-11-30
EA200001114A3 (ru) 2001-12-24
KR20010051983A (ko) 2001-06-25
NO317264B1 (no) 2004-09-27
SK285373B6 (sk) 2006-12-07
EA200001114A2 (ru) 2001-08-27
CA2326529C (en) 2009-12-22
GB0028566D0 (en) 2001-01-10
CN1152016C (zh) 2004-06-02
PE20010901A1 (es) 2001-09-20
NO20006012D0 (no) 2000-11-28
NZ508386A (en) 2003-02-28
YU73400A (sh) 2003-02-28
ITMI20002575A1 (it) 2002-05-29
CZ20004399A3 (cs) 2001-07-11
GEP20022763B (en) 2002-08-26
ZA200006964B (en) 2001-06-05
DE10058310A1 (de) 2001-05-31
JO2298B1 (en) 2005-09-12
SV2002000227A (es) 2002-02-05
PL195957B1 (pl) 2007-11-30
KR100390117B1 (ko) 2003-07-04
ATE253561T1 (de) 2003-11-15
DK1103545T3 (da) 2004-03-15
HUP0004725A2 (hu) 2002-04-29
ES2208205T3 (es) 2004-06-16
DE60006340D1 (de) 2003-12-11
BR0005616A (pt) 2001-07-17
HU224703B1 (en) 2006-01-30
AU7178700A (en) 2001-05-31
JP2001151754A (ja) 2001-06-05
BRPI0005616B1 (pt) 2017-12-12
DE60006340T2 (de) 2004-09-09
IT1320120B1 (it) 2003-11-18
MA26754A1 (fr) 2004-12-20
UY26458A1 (es) 2001-05-31
OA11513A (fr) 2004-02-03
DOP2000000106A (es) 2002-07-30
SI1103545T1 (en) 2004-02-29
TR200302077T4 (tr) 2004-01-21
TNSN00226A1 (fr) 2002-05-30
FR2801590A1 (fr) 2001-06-01
CA2326529A1 (en) 2001-05-29
SG97171A1 (en) 2003-07-18
GB2356863A (en) 2001-06-06
EP1103545B1 (en) 2003-11-05
MY127426A (en) 2006-11-30
PA8507201A1 (es) 2002-02-21

Similar Documents

Publication Publication Date Title
BG64622B1 (bg) 2-(3,5-бис-трифлуорометил-фенил)-n-метил-n-(6-морфолин-4-ил)-4-о-толил-пиридин-3-ил)-изобутирамид, метод за получаване и използването му
RU2276139C2 (ru) Производные 4-фенилпиридина и лекарственное средство
US6849624B2 (en) Aromatic and heteroaromatic substituted amides
EP1863767A1 (en) Metabolites for nk-i antagonists for emesis
JP4767973B2 (ja) Ｎｋ１アンタゴニスト
AU2002355652B8 (en) Aromatic and Heteroaromatic Substituted Amides
AU2002355652A1 (en) Aromatic and Heteroaromatic Substituted Amides
IL159571A (en) 2-(3,5-bis-trifluoromethyl-phenyl)-n-[6-(1,1,-dioxo-1lambda6-thiomorpholin-4-yl)-4-(2-methyl or 4-fluoro -2-methyl substituted) phenyl-pyridin-3-yl]-n-methylyl-isobutyramide, its preparation and pharmaceutical compositions comprising it